:

DASSAULT SYSTÈMES ACQUIRES DRUG TRIAL SOFTWARE FIRM

INDUSTRY DESK1 MIN READ
THU, JUL 23, 2026

■ AI-SUMMARIZED FROM 2 SOURCES ▸ TIMELINE

Dassault Systèmes SE is acquiring ArisGlobal, a drug trial software maker, for up to $2 billion. The deal marks the French company's continued expansion into life sciences software.

The acquisition positions Dassault Systèmes to strengthen its portfolio in pharmaceutical and clinical trial management. ArisGlobal provides software solutions for drug development and regulatory compliance, serving pharmaceutical and biotechnology companies worldwide. Dassault Systèmes, known for its 3D design and simulation platforms, has been diversifying beyond manufacturing into life sciences. This move aligns with broader industry trends as software becomes increasingly critical to accelerating drug development timelines and improving trial efficiency. The deal size—potentially reaching $2 billion—reflects the strategic value Dassault places on clinical trial digitalization. ArisGlobal's technology addresses growing demand for cloud-based platforms that streamline complex regulatory processes and data management in pharmaceutical research.

■ SOURCES

Bloomberg TechBloomberg Tech

■ SUMMARY WRITTEN BY AI FROM THE LINKS ABOVE

■ MORE FROM THE BIG TECH DESK

Google is rolling out a Live Game Feed feature for NFL games, offering real-time updates, play-by-play commentary, and AI-powered insights directly in search results on mobile.

3H AGOIndustry Desk

Florida's attorney general filed a lawsuit Wednesday against Netflix, claiming the streaming platform misleads parents about data collection practices on minors and uses design features that encourage excessive viewing.

3H AGOIndustry Desk

The American Federation of Teachers and Microsoft have agreed on privacy and safety standards for AI in educational settings, including legal liability provisions for data breaches.

4H AGOAI Desk

A New Yorker investigation reveals how Flock Safety's camera network and data practices create a surveillance infrastructure with limited oversight and few mechanisms for individuals to opt out.

6H AGOIndustry Desk

■ SUBSCRIBE TO THE DAILY BRIEF

ONE EMAIL, 5 STORIES, 06:00 UTC. UNSUBSCRIBE ANYTIME.